GSA Capital Partners’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $622K | Buy |
13,366
+2,810
| +27% | +$135K | 0.04% | 853 |
|
|
2026
Q1 | $546K | Buy |
10,556
+2,254
| +27% | +$115K | 0.03% | 859 |
|
|
2025
Q4 | $413K | Buy |
+8,302
| New | +$404K | 0.04% | 949 |
|
|
2025
Q3 | – | Sell |
-35,283
| Closed | -$1.11M | – | 2077 |
|
|
2025
Q2 | $1.11M | Sell |
35,283
-55,255
| -61% | -$1.77M | 0.08% | 388 |
|
|
2025
Q1 | $2.96M | Buy |
90,538
+71,478
| +375% | +$2.53M | 0.27% | 14 |
|
|
2024
Q4 | $689K | Sell |
19,060
-43,771
| -70% | -$1.54M | 0.05% | 670 |
|
|
2024
Q3 | $1.96M | Buy |
62,831
+43,086
| +218% | +$1.34M | 0.15% | 133 |
|
|
2024
Q2 | $528K | Buy |
19,745
+12,451
| +171% | +$361K | 0.04% | 928 |
|
|
2024
Q1 | $249K | Sell |
7,294
-1,031
| -12% | -$30.7K | 0.02% | 1305 |
|
|
2023
Q4 | $241K | Buy |
8,325
+1,038
| +14% | +$27.5K | 0.02% | 1230 |
|
|
2023
Q3 | $201K | Buy |
+7,287
| New | +$222K | 0.02% | 1286 |
|
|
2023
Q1 | – | Sell |
-16,394
| Closed | -$585K | – | 1922 |
|
|
2022
Q4 | $585K | Buy |
+16,394
| New | +$570K | 0.07% | 506 |
|
|
2022
Q2 | – | Sell |
-10,023
| Closed | -$324K | – | 1783 |
|
|
2022
Q1 | $324K | Buy |
+10,023
| New | +$307K | 0.04% | 840 |
|
|
2020
Q1 | – | Sell |
-42,925
| Closed | -$1.02M | – | 1530 |
|
|
2019
Q4 | $1.02M | Buy |
42,925
+33,039
| +334% | +$802K | 0.12% | 203 |
|
|
2019
Q3 | $272K | Buy |
+9,886
| New | +$293K | 0.04% | 989 |
|
|
2019
Q1 | – | Sell |
-8,700
| Closed | -$289K | – | 1686 |
|
|
2018
Q4 | $289K | Buy |
+8,700
| New | +$374K | 0.03% | 858 |
|
|
2018
Q3 | – | Sell |
-35,777
| Closed | -$2.14M | – | 1885 |
|
|
2018
Q2 | $2.14M | Sell |
35,777
-26,357
| -42% | -$1.37M | 0.11% | 239 |
|
|
2018
Q1 | $2.85M | Sell |
62,134
-5,000
| -7% | -$209K | 0.15% | 134 |
|
|
2017
Q4 | $2.67M | Buy |
67,134
+26,000
| +63% | +$1.03M | 0.16% | 111 |
|
|
2017
Q3 | $1.65M | Sell |
41,134
-67,600
| -62% | -$2.93M | 0.11% | 228 |
|
|
2017
Q2 | $4.69M | Sell |
108,734
-29,100
| -21% | -$1.04M | 0.31% | 13 |
|
|
2017
Q1 | $4.31M | Buy |
137,834
+11,005
| +9% | +$295K | 0.23% | 32 |
|
|
2016
Q4 | $3.2M | Buy |
126,829
+95
| +0.1% | +$2.12K | 0.19% | 62 |
|
|
2016
Q3 | $3.13M | Sell |
126,734
-83,695
| -40% | -$1.89M | 0.17% | 88 |
|
|
2016
Q2 | $4.29M | Sell |
210,429
-41,680
| -17% | -$739K | 0.24% | 31 |
|
|
2016
Q1 | $3.85M | Buy |
252,109
+32,537
| +15% | +$425K | 0.25% | 27 |
|
|
2015
Q4 | $2.95M | Buy |
219,572
+5,193
| +2% | +$80.3K | 0.14% | 129 |
|
|
2015
Q3 | $3.01M | Buy |
214,379
+94,973
| +80% | +$1.77M | 0.15% | 117 |
|
|
2015
Q2 | $2.03M | Buy |
+119,406
| New | +$1.7M | 0.08% | 366 |
|
Other funds holding SUPN
AC
NAMI
SIMG
GSA Capital Partners's SUPN Position: Q2 2026 in Review
GSA Capital Partners increased its Supernus Pharmaceuticals (SUPN) stake by 27% in Q2 2026, buying an estimated $135K and bringing the position to 13,366 shares worth $622K. The position accounts for 0.04% of the portfolio, ranked #853.
GSA Capital Partners first reported a position in SUPN in Q2 2015 and has held it in 29 quarters since. The position peaked at $4.69M in Q2 2017. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- GSA Capital Partners held 13,366 shares of Supernus Pharmaceuticals worth $622K as of Q2 2026.
- GSA Capital Partners bought 2,810 Supernus Pharmaceuticals shares in Q2 2026, an estimated $135K.
- Supernus Pharmaceuticals made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #853 holding.
- GSA Capital Partners first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 29 quarters since.
- GSA Capital Partners's Supernus Pharmaceuticals position peaked at $4.69M in Q2 2017.
- 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.